There’s a big change in Amarin’s (AMRN) C-Suite and it looks like the Street is not happy about it. Shares took a beating in Tuesday’s trading session after the biotech company announced the departure of CEO John F. Thero. Thero who will retire on August 1, has been with Amarin for twelve years, and at the helm for the last seven. Karim Mikhail will take over his role. Mikhail is currently the head of commercial for Europe and joined Amarin in 2020. Mikhail held various executive roles at Merck and has considerable expertise in bringing to market lipid therapies in the EU.
https://www.tipranks.com/news/article/amarin-could-the-new-ceo-help-vazkepas-european-push